Chris Nabel

Christopher Nabel is a medical oncologist and researcher at MIT's Koch Institute. His interdisciplinary work explores how cancer metabolism drives immunotherapy resistance, focusing on adenosine accumulation in tumor microenvironments.

He develops computational models of metabolic pathways that suppress immune responses, seeking pharmacological interventions to restore anti-tumor immunity. His approach combines molecular biology with clinical informatics.

Recent studies examine spatial accessibility to healthcare in resource-limited settings and spatiotemporal patterns of COVID-19 hospitalization.

He collaborates with Massachusetts General Hospital on translational oncology projects.